Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024
07 May, 2014, 14:00 BST
LONDON, May 7, 2014 /PRNewswire/ --
Biosimilar drugs - discover trends and segments with highest potential revenues
Do you want to find sales potentials of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2014, helping you stay ahead. For those therapies you find financial data, R&D trends, opportunities and selling prospects.
In that new analysis you get sales forecasts to 2024 at overall world market, therapeutic class, molecule and national level. You also assess trends, technologies and expected products, benefiting your reputation for technological, clinical and commercial insight.
Developments in that industry - see what's possible for those biotech medicines
There you explore what the future holds for biosimilars (follow-on biologics, follow-on protein products). So read on to investigate that industry and hear what future sales it could achieve.
Forecasts and other analyses explain the best financial prospects
In our study you find revenue forecasting to 2024, historical results, growth rates and market shares. There you get quantitative and qualitative analysis, business news and research and development (R&D). You also gain 104 tables, 76 charts and two company interviews.
Many opportunities exist for those competitors of original biological drugs (biologics). You discover segments most likely to prosper. Finding data you need just got easier. There help your research, analyses and plans, increasing your chances of success.
And the following sections show how you benefit from that new analysis.
Predictions for that world market and its submarkets
Along with revenue prediction for the overall world market for biosimilars, our work shows forecasts to 2024 for its individual submarkets:
• Monoclonal antibodies (mAbs) and fusion proteins (FPs) - including rituximab, infliximab, trastuzumab, adalimumab and etanercept segments
• Insulins - inc. submarkets of human insulin and analogues, as well as insulin glargine and insulin lispro
• Erythropoietins (EPO)
• Granulocyte colony-stimulating factors (G-CSF)
• Interferons - inc. alpha and beta segments
• Growth hormones (hGH, somatropin)
• Fertility hormones
That report shows you revenue potentials of those biopharmaceuticals, helping you find chances to develop your business. Also benefit your authority on those treatments.
Our investigation also discusses what stimulates and restrains sales of those subsequent entry biologics. You explore that industry, seeing what products can achieve the most success.
Comparisons of biosimilar drug sales with those of the overall biologics market
You also discover revenues to 2024 for the overall biologics market and its segments. There find how the biosimilars market compares at world level. See how market share can expand.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Our study also divides its forecasting into geographical regions.
National markets for those therapeutic proteins - where will highest sales and growth occur?
Developments worldwide will influence that follow-on biologics market, raising demand for biosimilars in developed and developing countries. See how and where.
Our analyses show you individual revenue forecasts to 2024 for 12 national markets and one regional block:
• United States (US)
• Japan
• European Union (EU) and leading members - Germany, France, UK, Italy and Spain
• BRIC nations - Brazil, Russia, India and China
• South Korea.
There you discover progress and outlooks. You assess the biosimilar industry's future - hear about developments and find their significance. Our work explains, exploring issues.
Forces affecting that biopharmaceutical industry and market
That new report discusses issues and events affecting the industry and market from 2014, including these developments:
• Considerations for developing biosimilars - challenges and opportunities
• Guidelines from regulators and what they mean for developers and producers
• Needs and challenges in developing biosimilar mAbs
• Developments in technology to aid biosimilar drug production
• Collaborations among companies for making those biopharmaceutical molecules.
That study also discusses other aspects of those biotech drugs, including these:
• Incidence and prevalence of diseases affecting treatment needs
• Economics stimulating demand for substitute biological medicines
• Biobetters as rivals of biosimilars
• Patent challenges and data exclusivity for biopharmaceuticals
• Outsourcing to gain expertise in pharma biotechnology and production efficiencies.
There you assess that industry's strengths, weaknesses, opportunities and threats (SWOT), also exploring social, technological, economic and political questions. And you get Porter's Five Forces analysis. So you gain feel for that sector and its progress.
Discover, then, what the future holds, benefiting your reputation for commercial insight.
Companies and 2018 market value - what's possible?
From 2014, product launches there hold great potential for investments, uptake and sales. Our study predicts the world market for biosimilars and related follow-on biologics will reach $9.2bn in 2018, and multiply in size to 2024. See how high revenues can go.
You assess there what biosimilar technologies, products types and companies hold most potential. Our analyses cover these firms and many other developers, producers and sellers:
• Sandoz (Novartis)
• Hospira
• Mylan
• Pfizer
• Merck & Co.
• Boehringer Ingelheim
• Dr. Reddy's Laboratories
• Teva Pharmaceutical Industries.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
In our report you find 245 organisations mentioned. You also get interviews with authorities in the industry. Hear what shapes it, discovering what participants say and do.
From this decade there will arise many sales opportunities. Prospects for those rivals of established biologics are strong. See what holds greatest potential. Our work shows you technological and commercial possibilities for those substitutes, helping you stay ahead.
Ways Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 helps
In particular, then, our investigation gives you the following knowledge to benefit your work:
• Revenues to 2024 at overall world level and for biological drug and biosimilar submarkets - assess outlooks for production, marketing and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe and Asia - appraise developed and developing countries for potential revenues
• Prospects for established competitors and rising companies - explore portfolios, results, R&D, opinions from interviews and outlooks for success.
Data there found nowhere else, benefiting your authority on pharma biotechnology
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you're less likely to fall behind in information or miss opportunity. See there how you can benefit your searches, analyses and decisions, also saving time and helping your influence.
Our new investigation is for everyone assessing the present and future of biological drugs. There you find data, trends, opportunities and sales predictions. So please get that report here now.
Companies listed in this report
3SBio
AbbVie
Aché
Actavis
Adocia
AET BioTech
Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) [France]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agenzia Italiana del Farmaco (AIFA)
Agila Biotech (part of Strides Arcolab)
Alliance for Safe Biologic Medicines (ASBM)
Allozyne
Alteogen
Alvogen
Amarey Nova Medical
Ambrx
Amega Biotech
Amgen
Antares Pharma
Apotex
Aprogen
Aryogen Biopharma
Astellas Pharma
AstraZeneca
Avesthagen
Baxter International
Bayer
Beijing Four Rings Pharmaceutical
Beijing SL Pharmaceutical
Binex Co.
Biocad
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biodel
Biogen Idec
BioGeneriX (part of Teva)
BioGenomics
Biolab Sanus Farmacêutica
Bionovis
Biopartners (part of Bioton)
Biosidus
Bioton
Boehringer Ingelheim
Brazilian Ministry of Health
Bristol-Myers Squibb
Cardiovascular and Renal Drugs Advisory Committee [US]
CCL Pharmaceuticals
CCM Duopharma Biotech
Celltrion
Centers of Medicare and Medicaid Services (CMS)
Central Drugs Standard Control Organisation (CDSCO) [India]
China Food and Drug Administration (CFDA)
Chong Kun Dang
Chugai Pharmaceutical (part of Roche)
CinnaGen
Cipla
Coherus BioSciences
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Compass Biotechnologies
CT Arzneimittel (part of Teva)
Daewoong Pharmaceutical
Daiichi Sankyo
Dance Biopharm
Dem Pharmaceuticals
Department of Biotechnology [India]
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Drug Regulatory Authority of Pakistan (DRAP)
Egis Pharmaceuticals
Eli Lilly
Elpen Pharmaceutical
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
Emcure Pharmaceuticals
EMS
Epirus Biopharmaceuticals
Eurofarma Laboratórios
European Commission
European Medicines Agency (EMA)
Europharm
EvaluatePharma (now Evaluate)
Express Scripts
FDA Center for Drug Evaluation and Research (CDER) [US]
FibroGen
Finox
Fuji Pharma
Fujifilm
Fujifilm Kyowa Kirin Biologics
Gan & Lee Pharmaceutical
Gedeon Richter
Gene Techno Science
Genentech (part of Roche)
International Biotech Center Generium (Generium)
Genexine
Gennova Biopharmaceuticals (part of Emcure Pharmaceuticals)
GeneScience Pharmaceuticals (GenSci)
Genzyme (part of Sanofi)
Geropharm
Gilead Sciences
GlaxoSmithKline (GSK)
Halozyme Therapeutics
Hangzhou Jiuyuan Gene Engineering
Hanmi Pharmaceutical
Hanwha Chemical
Haselmeier
Health Canada
Henlius Biotech
Hexal (part of Novartis)
Hikma Pharmaceuticals
Hindustan Anti Biotech
Hospira
Hualida Biotech
Hypermarcas
IGES Institut [Germany]
Innovare R&D
Insmed
Instituto Vital Brazil
Intas Biopharmaceuticals
Intellectual Property Appellate Board (IPAB) [India]
International Diabetes Federation (IDF)
inVentiv Health
Isu Abxis
Johnson & Johnson (J&J)
JCR Pharmaceuticals
Kemwell Biopharma
Kissei Pharmaceutical
Koçak Farma
Kwizda Pharma
Kyowa Hakko Kirin
Laboratorios Delta
Landsteiner Scientific
LG Life Sciences
Libbs Farmacêutica
LMC
Lonza
Mabion
mAbxience
MannKind
Marvel Life Sciences
Medice
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck Serono
Minapharm Pharmaceuticals
Ministry of Food and Drug Safety (MFDS) [South Korea]
Ministry of Health and Medical Education [Iran]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mycenax Biotech
Mylan
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute for the Control of Pharmaceutical and Biological Products [China]
Nichi-Iko Pharmaceutical
Nippon Kayaku
Norwegian Ministry of Health
NovaQuest Capital Management
Novartis
Novo Nordisk
Nuron Biotech
Oncobiologics
OPKO Health
Organon (part of Merck & Co.)
Ortho Pharmaceutical (now Janssen Pharmaceuticals)
Orygen Biotecnologia
PanGen Biotech
Parexel International
Pfenex
Pfizer
Pharmapark (part of Pharmstandard)
PharmaPraxis
Pharmstandard
PlantForm
Pliva (part of Teva)
PRA International
Pro Generika [Germany]
Probiomed
Prolor Biotech (part of OPKO Health)
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
ratiopharm (part of Teva)
Regeneron Pharmaceuticals
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Life Sciences
Rentschler Biotechnologie
Roche
Russian Ministry of Health
SAFC
Samsung
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
Sanwa Kagaku Kenkyusho
SciGen (part of Bioton)
Scottish Medicines Consortium (SMC)
Seattle Genetics
Shandong Kexing Bioproducts
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian Pharmaceutical
Shanghai Fosun Pharmaceutical
Shantha Biotechnics
Sicor Biotech (part of Teva)
Sothema Laboratories
Spectrum Pharmaceuticals
Stada Arzneimittel
Stanford University
State Employees' Social Security and Social Services Institute (ISSSTE) [Mexico]
Stragen Pharma
Strides Arcolab
Syngene International
Synthon Biopharmaceuticals
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
The United Laboratories
Therapeutic Goods Administration (TGA) [Australia]
Thermalin Diabetes
Tianjin Hualida Biotechnology
Tonghua Dongbao
University of Toronto
TSH Pharma
UMN Pharma
União Química
University of California, Los Angeles (UCLA)
University of California, San Francisco (UCSF)
US Centers for Disease Prevention and Control (CDC)
US Food and Drug Administration (FDA)
US Patent and Trademark Office (USPTO)
USV Biologics
Virchow Biotech
Wangbang Biopharmaceuticals (part of Shanghai Fosun)
Wockhardt
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Xeris Pharmaceuticals
Xiamen Amoytop Biotech
Yakult Honsha
Ypsomed
Zenotech Laboratories
Zhejiang Huahai Pharmaceutical
Zuventus Healthcare (part of Emcure Pharmaceuticals)
Zydus Cadila
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100
SOURCE Visiongain